Review Article

(Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity

Table 4

Examples of immune reaction after xenogenic or allogeneic MSC transplantation.

MSC originRecipient, route of transplantationAdverse immune reactionRef.

Allogeneic
Ad or BM
Healthy horses; intravenous injection, 3 times D0, D14, D28Day 35: ↑ circulating CD8+ T cells after multiple iv injections of BM MSCs[6]

Xenogeneic hBMSprague-Dawley rats:
Intracardiac injection
(i) Immunocompetent
(ii) Immunosuppressed (tacrolimus)
(iii) RNU athymic rats
↑ macrophages in myocardium of immunocompetent rats from day 2 to day 7;
MLR test (peripheral blood of rats mixed with 1% or 10% of MSCs) showed ↑ lymphocyte proliferation in SD rats previously exposed to MSCs
[62]

Xenogeneic
hESCs
Healthy mice, immunocompetentInfiltrates of T cells and macrophages around injected MSCs; MSCs disappeared 3 days after transplantation (acute rejection)[58]

Xenogeneic
hBM
Rats
Intracardiac injection
RNU athymic rats
RNU + tacrolimus
Fisher + tacrolimus
Cells were present 6 weeks after transplantation in RNU rats with additional immunosuppression, in RNU rats without additional immunosuppression (tacrolimus) or in Fisher rats with immunosuppression no surviving hMSCs were found[63]

Allogeneic or syngeneic
BM MSCs
Wistar and Lewis rats;
Intracardiac injection immunocompetent
Allogeneic MSCs caused T cell and B cell activation and stimulated the humoral immune system to produce antibodies against the allogeneic cells—function was lost after 5 months[64]

Allogeneic, syngeneic, and third party
BM MSCs
BALB/c or B6 mice;
Sublethally irradiated mice intravenous injection
The addition of host (syngeneic) MSCs enhanced engraftment, while the infusion of donor (allogeneic) MSCs was associated with increased rejection of allogeneic donor BM cells and induce a memory T cell response. Third-party MSCs had a neutral effect on engraftment.[65]

Allogenic donor/recipient MSCsRats: Lewis (donor), ACI (recipients); heart transplantation with or without immunosuppression (CsA)Allogeneic MSCs did not prolong allograft survival. Treatment with low-dose CsA and MSCs accelerate allograft rejection in a rat heart transplant model[66]

BM: bone marrow; Ad: adipose tissue; hESC: human embryonic stem cells; CsA: cyclosporine A; Third party: commercially available; MLR: mixed-lymphocyte reaction; RNU: Rowett nude rats (athymic with the genotype rnu/rnu).